Zymeworks, an oncology biotech known for its HER2-targeting cancer drugs, just dropped $929 million to buy a COPD lung treatment. The financing structure is clever, the strategic logic is surprisingly sound, and the real test comes in August.
Imagine you've spent your entire career training to be a sushi chef. You're good at it. You're getting recognized. Then one day, you buy a barbecue restaurant.
That's basically what Zymeworks just did.
The oncology-focused biotech agreed to acquire Theravance Biopharma for $929 million in cash, picking up Yupelri, an FDA-approved once-daily nebulized treatment for COPD (chronic obstructive pulmonary disease, the lung condition that makes breathing feel like sucking air through a coffee stirrer). The deal marks one of the most unexpected therapeutic pivots in recent biotech memory.
A Cancer Company Walks Into a Pharmacy
Zymeworks has built its reputation on fighting cancer. Its lead drug, zanidatamab (branded as Ziihera), is a bispecific antibody that grabs onto two different spots on the HER2 protein at once, like a molecular wrestling hold. It's under FDA Priority Review for HER2-positive stomach cancer, with a decision date of August 25, 2026. The company also has a pipeline full of antibody-drug conjugates (ADCs), basically guided missiles that deliver chemo directly to tumor cells.
So why buy a COPD drug? Because cancer companies live and die by binary events. One failed trial can crater your stock. One approval can double it. Yupelri offers something oncology rarely provides: predictable, growing, commercial revenue right now.
The Asset That Makes This Deal Work
Yupelri isn't some speculative pipeline bet. It's been on the market since 2018, and it's the only once-daily nebulized bronchodilator for COPD maintenance in the U.S. Think of a nebulizer as a breathing machine that turns liquid medication into a mist; it's especially useful for patients who can't handle handheld inhalers, including older and homebound patients.
The sales trajectory tells the story. Yupelri brought in $238.6 million in U.S. net sales in 2024, up 8% from the prior year. In 2025, that number jumped to $266.6 million, boosted by improved pricing and a surge in hospital adoption (hospital doses grew 49% year-over-year in Q4 2024 alone). By Q1 2026, sales were still climbing at a 7% clip.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
This isn't a blockbuster. It's a niche product with steady growth in a massive disease category. And for a company like Zymeworks, which lives in the volatile world of clinical-stage oncology, that kind of consistency is like finding a savings account that actually pays interest.
How Zymeworks Is Paying Without Breaking the Bank
The financing structure is arguably the cleverest part of this deal. Zymeworks isn't issuing a single new share to pay for Theravance, meaning zero dilution for existing shareholders. Instead, the company assembled a three-part funding stack:
First, a $350 million loan from OMERS Life Sciences, backed entirely by Yupelri's future cash flows. If Yupelri revenue dries up, OMERS eats the loss; Zymeworks' other assets remain untouched. That loan carries an 8.25% interest rate and is expected to mature around 2036.
Second, Theravance itself is sitting on roughly $360 million in cash at closing. So Zymeworks is essentially using the target's own wallet to fund part of the purchase price.
Third, Zymeworks is contributing about $219 million from its own balance sheet, with management noting that approximately $100 million of that should come back via near-term milestone payments in early 2027.
It's a bit like buying a house where the seller left cash in the safe, and your mortgage is secured only by the rental income from the property. Smart structuring.
The CVR: A Lottery Ticket for Shareholders
Theravance shareholders get $17.00 per share in cash, representing a 22% premium over the stock's closing price on March 3, 2026 (the day Theravance announced Phase 3 results for another drug called ampreloxetine). They also receive one contingent value right, or CVR, per share.
The CVR is essentially a lottery ticket tied to ampreloxetine's future. If Zymeworks licenses, sells, or otherwise monetizes the drug over the next 10 years, CVR holders get 80% of the proceeds. There's also a $50 million milestone if ampreloxetine hits its first commercial sale, plus a 10% cut of future net sales. Not bad for a drug that Zymeworks clearly bought as a side dish, not the main course.
Analyst reactions were lukewarm. BTIG downgraded Theravance to Neutral, treating the $17 deal price as a ceiling rather than a floor. The stock traded around $16.93 to $16.98 after the announcement, suggesting Wall Street sees this closing without drama.
Why This Pivot Isn't as Crazy as It Sounds
Zymeworks isn't the first oncology company to look outside the tumor ward for stability. Merck recently paid roughly $10 billion for Verona Pharma, grabbing the COPD drug ensifentrine to diversify away from its Keytruda patent cliff. BioMarin spent $4.8 billion on Amicus Therapeutics to broaden its rare disease footprint. Biogen has been reshaping itself around neurodegeneration.
The playbook is consistent: when your core business depends on high-stakes binary outcomes (will this drug get approved or won't it?), you buy something that generates cash while you wait. Yupelri is that something.
Zymeworks is also building its own respiratory story from scratch. The company's pipeline includes ZW1528, a bispecific molecule targeting two inflammation pathways (IL-4Rα and IL-33) in COPD patients. An IND filing is planned for 2027. So the Theravance deal doesn't just buy revenue; it buys credibility and commercial infrastructure in a disease area where Zymeworks already has scientific ambitions.
The Competitive Reality Check
Yupelri's niche is comfortable but not uncontested. The broader COPD market is dominated by GSK, AstraZeneca, and Boehringer Ingelheim, companies with decades of respiratory expertise and multi-billion-dollar inhaler franchises. Yupelri competes more narrowly in the nebulized segment, where its once-daily convenience gives it an edge among patients who struggle with traditional inhalers.
But there's a cloud on the horizon. Lupin recently received tentative FDA approval for a generic version of revefenacin (Yupelri's active ingredient). Generic entry could eventually pressure pricing and slow growth. Zymeworks is betting that by the time generics bite, the OMERS loan will be substantially paid down, and zanidatamab royalties will be flowing.
The Bottom Line
This deal is a calculated bet on balance. Zymeworks gets a growing commercial asset to smooth out the volatility of oncology drug development. Theravance shareholders get a solid premium plus a free option on ampreloxetine. And the financing structure keeps Zymeworks' balance sheet intact for its cancer pipeline.
The real test comes in August, when the FDA rules on zanidatamab for stomach cancer. If that gets approved, Zymeworks becomes a rare thing in biotech: a company with revenue from two completely different therapeutic areas, funded without a single new share. If it doesn't, well, at least Yupelri will keep the lights on.
Clinical & Regulatory
4 min read
The World's Biggest Generics Maker Just Came for Ozempic's Crown
Sandoz just got FDA acceptance for generic versions of Eli Lilly's blockbuster weight-loss drug tirzepatide, setting up a long-game challenge to the $100 billion GLP-1 market. Patents keep the launch years away, but the world's biggest generics maker is already plotting price cuts that could reshape who gets access to obesity treatment.
